Schizophrenia Research

• 

  Publication Venue For

  • Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS)..  210:30-38. 2019
  • Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial..  208:182-189. 2019
  • The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies..  208:439-440. 2019
  • Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome..  204:320-325. 2019
  • Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia..  204:155-161. 2019
  • Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis..  201:85-90. 2018
  • Genetic correlates of insight in schizophrenia..  195:290-297. 2018
  • The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project..  195:306-317. 2018
  • Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia..  193:83-90. 2018
  • Deviation from expected cognitive ability across psychotic disorders..  192:300-307. 2018
  • Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients..  190:172-179. 2017
  • Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis..  190:160-163. 2017
  • Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up..  189:37-42. 2017
  • Completing the puzzle: The search for pieces in the understanding of psychosis risk in 22q11.2 deletion syndrome..  188:33-34. 2017
  • Validation of the tablet-administered Brief Assessment of Cognition (BAC App)..  181:100-106. 2017
  • Validation of a Computerized test of Functional Capacity..  175:90-96. 2016
  • Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia..  171:187-194. 2016
  • Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives..  170:156-161. 2016
  • Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment..  166:310-315. 2015
  • A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy..  164:136-142. 2015
  • Actigraphic-measured sleep disturbance predicts increased positive symptoms in adolescents at ultra high-risk for psychosis: A longitudinal study..  164:15-20. 2015
  • Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS)..  164:8-14. 2015
  • Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls..  164:47-52. 2015
  • Latent class analysis of discordance between results of drug use assessments in the CATIE data..  161:434-438. 2015
  • The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial..  160:180-185. 2014
  • Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit..  159:491-498. 2014
  • Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies..  159:205-210. 2014
  • Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery..  159:182-187. 2014
  • The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore..  156:233-240. 2014
  • Converting positive and negative symptom scores between PANSS and SAPS/SANS..  152:289-294. 2014
  • Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis..  151:148-153. 2013
  • Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis..  151:141-147. 2013
  • The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective..  151:279-283. 2013
  • Unraveling the relationship between obesity, schizophrenia and cognition..  151:107-112. 2013
  • Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia..  150:328-333. 2013
  • Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis..  150:542-546. 2013
  • Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study..  148:126-129. 2013
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial..  146:190-195. 2013
  • Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care..  146:217-223. 2013
  • Emotion recognition and social/role dysfunction in non-clinical psychosis..  143:70-73. 2013
  • Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study..  142:153-158. 2012
  • BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis..  140:65-70. 2012
  • Heritability of functioning in families with schizophrenia in relation to neurocognition..  139:105-109. 2012
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder..  138:35-38. 2012
  • Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia..  136:25-31. 2012
  • Insomnia is frequent in schizophrenia and associated with night eating and obesity..  133:238-243. 2011
  • Substance use and schizophrenia: adverse correlates in the CATIE study sample..  132:177-182. 2011
  • Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study..  130:47-52. 2011
  • The association between weight change and symptom reduction in the CATIE schizophrenia trial..  128:166-170. 2011
  • Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone..  127:188-194. 2011
  • The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study..  126:124-131. 2011
  • Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial..  125:161-168. 2011
  • Attention deficits in schizophrenia--preliminary evidence of dissociable transient and sustained deficits..  122:104-112. 2010
  • The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition..  121:24-31. 2010
  • Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis..  119:95-100. 2010
  • Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial..  116:118-125. 2010
  • The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial..  115:17-23. 2009
  • Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial..  113:12-18. 2009
  • Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study..  111:9-16. 2009
  • Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. 2018
  • Cognitive burden of anticholinergic medications in psychotic disorders. 2017
  • Neuropsychological functions of prefrontal cortex are selectively impaired early in the course of schizophrenia